F Fuzkk Atlas of the USA
#326Extended selection 101–500

Jubilant Radiopharma

Mid-Atlantic / Southeast

Radiopharmaceuticals

Manufacturing profile

Radiopharmaceuticals

Biopharma hub: Mid-Atlantic / Southeast

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Radionuclide production or generator handling
  2. 2Shielded synthesis and hot-cell operations
  3. 3Sterile filtration and aseptic dispensing
  4. 4Activity, identity and radionuclidic/radiochemical purity
  5. 5Rapid release, sterility/endotoxin evidence and timed distribution

Relevant FUZKK packages

United States: national essential medicines QC packageRPH: combined radiopharmaceutical QC packageRadioligand & Theranostics Expansion QC Suite

Product/API utilities

Radionuclidic Purity CheckerCold Chain Shipping Temperature And MKT Quality Checker

Lumex — instrumental QC

System Suitability Parameters Checker

LabEx — laboratory QC

Bacterial Endotoxins LAL Quality CheckerSterility Test Membrane Filtration Quality CheckerParticle Count Injection USP <788> Quality Checker

Medical Devices — equipment and software lifecycle

Supplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology